Eaton Vance Management’s Accelerate Diagnostics AXDX Stock Holding History

Eaton Vance Management’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$339K	Hold	22,322	–	–	﹤0.01%	1404
2022 Q2	$222K	Hold	22,322	–	–	﹤0.01%	1509
2022 Q1	$321K	Hold	22,322	–	–	﹤0.01%	1617
2021 Q4	$1.17M	Hold	22,322	–	–	﹤0.01%	1150
2021 Q3	$1.3M	Hold	22,322	–	–	﹤0.01%	1026
2021 Q2	$1.8M	Hold	22,322	–	–	﹤0.01%	1036
2021 Q1	$1.86M	Hold	22,322	–	–	﹤0.01%	993
2020 Q4	$1.69M	Hold	22,322	–	–	﹤0.01%	961
2020 Q3	$2.38M	Hold	22,322	–	–	﹤0.01%	798
2020 Q2	$3.38M	Hold	22,322	–	–	0.01%	687
2020 Q1	$1.86M	Hold	22,322	–	–	﹤0.01%	771
2019 Q4	$3.77M	Hold	22,322	–	–	0.01%	691
2019 Q3	$4.14M	Hold	22,322	–	–	0.01%	633
2019 Q2	$5.11M	Hold	22,322	–	–	0.01%	579
2019 Q1	$4.69M	Hold	22,322	–	–	0.01%	569
2018 Q4	$2.57M	Hold	22,322	–	–	0.01%	657
2018 Q3	$5.12M	Hold	22,322	–	–	0.01%	543
2018 Q2	$4.98M	Hold	22,322	–	–	0.01%	528
2018 Q1	$5.1M	Hold	22,322	–	–	0.01%	503
2017 Q4	$5.85M	Hold	22,322	–	–	0.01%	485
2017 Q3	$5.01M	Buy	+22,322	New	+$5.48M	0.01%	506

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Eaton Vance Management's AXDX Position: Q3 2022 in Review

Eaton Vance Management held its Accelerate Diagnostics (AXDX) position steady in Q3 2022 at 22,322 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #1404.

Eaton Vance Management first reported a position in AXDX in Q3 2017 and has held it in 21 quarters since. The position peaked at $5.85M in Q4 2017. 84 funds tracked by Wall St. Rank hold AXDX as of Q3 2022.

Eaton Vance Management held 22,322 shares of Accelerate Diagnostics worth $339K as of Q3 2022.
Eaton Vance Management left its Accelerate Diagnostics share count unchanged in Q3 2022.
Accelerate Diagnostics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1404 holding.
Eaton Vance Management first reported a position in Accelerate Diagnostics in Q3 2017 and has held it in 21 quarters since.
Eaton Vance Management's Accelerate Diagnostics position peaked at $5.85M in Q4 2017.
84 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.